Bachem Shows Strong Growth in the First Half of 2025
Bachem (OTC:BCHMY) reported robust financial results for H1 2025, with sales reaching CHF 313.0 million, marking a significant increase of 30.2% (34.1% in local currencies) compared to the prior year. The company's EBITDA surged 64% to CHF 91.0 million, with margin expanding to 29.1% from 23.1%.
Commercial API sales grew 32.4% to CHF 168.4 million, while Clinical Development revenue increased 36.9% to CHF 123.7 million. The company has raised its 2025 guidance to 13-18% sales growth and invested CHF 129.1 million in capacity expansion during H1.
Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.
Bachem (OTC:BCHMY) ha riportato risultati finanziari solidi per il primo semestre del 2025, con vendite che hanno raggiunto CHF 313,0 milioni, segnando un aumento significativo del 30,2% (34,1% a valute locali) rispetto all'anno precedente. L'EBITDA dell'azienda è aumentato del 64% raggiungendo CHF 91,0 milioni, con un margine che è salito al 29,1% dal 23,1%.
Le vendite commerciali di API sono cresciute del 32,4% arrivando a CHF 168,4 milioni, mentre i ricavi dello sviluppo clinico sono aumentati del 36,9% raggiungendo CHF 123,7 milioni. L'azienda ha rivisto al rialzo le previsioni per il 2025, prevedendo una crescita delle vendite tra il 13 e il 18%, e ha investito CHF 129,1 milioni nell'espansione della capacità produttiva nel primo semestre.
Guardando al futuro, Bachem punta a raggiungere vendite annue superiori a CHF 1 miliardo e un margine EBITDA superiore al 30% entro il 2026, supportata da investimenti significativi, tra cui il nuovo stabilimento Building K e l'espansione pianificata a Sisslerfeld.
Bachem (OTC:BCHMY) reportó resultados financieros sólidos para el primer semestre de 2025, con ventas que alcanzaron CHF 313,0 millones, lo que representa un incremento significativo del 30,2% (34,1% en monedas locales) en comparación con el año anterior. El EBITDA de la compañía aumentó un 64% hasta CHF 91,0 millones, con un margen que se expandió al 29,1% desde el 23,1%.
Las ventas comerciales de API crecieron un 32,4% hasta CHF 168,4 millones, mientras que los ingresos por Desarrollo Clínico aumentaron un 36,9% hasta CHF 123,7 millones. La compañía ha elevado su pronóstico para 2025, esperando un crecimiento de ventas entre el 13 y el 18%, e invirtió CHF 129,1 millones en la expansión de capacidad durante el primer semestre.
De cara al futuro, Bachem aspira a alcanzar ventas anuales superiores a CHF 1.000 millones y un margen EBITDA superior al 30% para 2026, respaldado por inversiones importantes, incluyendo la nueva instalación Building K y la expansión planificada en Sisslerfeld.
Bachem (OTC:BCHMY)은 2025년 상반기에 견고한 재무 실적을 보고했으며, 매출은 3억 1,300만 CHF에 달해 전년 대비 30.2%(현지 통화 기준 34.1%) 크게 증가했습니다. 회사의 EBITDA는 64% 급증하여 9,100만 CHF를 기록했으며, 마진은 23.1%에서 29.1%로 확대되었습니다.
상업용 API 매출은 32.4% 증가하여 1억 6,840만 CHF를 기록했고, 임상 개발 수익은 36.9% 증가하여 1억 2,370만 CHF에 이르렀습니다. 회사는 2025년 매출 성장 전망을 13~18%로 상향 조정했으며, 상반기에 1억 2,910만 CHF를 설비 확장에 투자했습니다.
앞으로 Bachem은 2026년까지 연간 매출 10억 CHF 이상과 30% 이상의 EBITDA 마진 달성을 목표로 하며, 신규 Building K 시설과 Sisslerfeld에서 계획된 확장 등 대규모 투자가 이를 뒷받침할 예정입니다.
Bachem (OTC:BCHMY) a publié des résultats financiers solides pour le premier semestre 2025, avec un chiffre d'affaires atteignant 313,0 millions de CHF, soit une augmentation significative de 30,2 % (34,1 % en devises locales) par rapport à l'année précédente. L'EBITDA de la société a bondi de 64 % pour atteindre 91,0 millions de CHF, avec une marge passant de 23,1 % à 29,1 %.
Les ventes commerciales d'API ont augmenté de 32,4 % pour atteindre 168,4 millions de CHF, tandis que les revenus du développement clinique ont progressé de 36,9 % pour atteindre 123,7 millions de CHF. La société a relevé ses prévisions pour 2025, anticipant une croissance des ventes entre 13 et 18 %, et a investi 129,1 millions de CHF dans l'expansion de ses capacités au premier semestre.
Pour l'avenir, Bachem vise à réaliser un chiffre d'affaires annuel supérieur à 1 milliard de CHF et une marge EBITDA supérieure à 30 % d'ici 2026, soutenue par des investissements importants, notamment la nouvelle installation Building K et l'extension prévue à Sisslerfeld.
Bachem (OTC:BCHMY) meldete robuste Finanzergebnisse für das erste Halbjahr 2025 mit einem Umsatz von 313,0 Mio. CHF, was einem deutlichen Anstieg von 30,2 % (34,1 % in Lokalwährungen) gegenüber dem Vorjahr entspricht. Das EBITDA des Unternehmens stieg um 64 % auf 91,0 Mio. CHF, wobei die Marge von 23,1 % auf 29,1 % expandierte.
Der Verkauf von kommerziellen APIs wuchs um 32,4 % auf 168,4 Mio. CHF, während die Erlöse aus der klinischen Entwicklung um 36,9 % auf 123,7 Mio. CHF zunahmen. Das Unternehmen hat seine Prognose für 2025 auf ein Umsatzwachstum von 13-18 % angehoben und im ersten Halbjahr 129,1 Mio. CHF in den Kapazitätsausbau investiert.
Mit Blick auf die Zukunft strebt Bachem an, bis 2026 einen Jahresumsatz von über 1 Mrd. CHF und eine EBITDA-Marge von über 30 % zu erreichen, unterstützt durch bedeutende Investitionen, darunter die neue Anlage Building K und die geplante Erweiterung in Sisslerfeld.
- None.
- Research & Specialties business declined 8.5% to CHF 20.8 million
- Significant capital expenditure requirements with over CHF 400 million planned for 2025
- GMP production in Building K still pending regulatory inspections
Bubendorf, Switzerland--(Newsfile Corp. - July 24, 2025) - Ad hoc announcement pursuant to Art. 53 LR
| Media Release |
Bachem shows strong growth in the first half of 2025
- Group sales showed strong growth reaching CHF 313.0 million (+
30.2% compared to the prior-year period, +34.1% in local currencies). - EBITDA grew to CHF 91.0 million (+
64.0% compared to the prior-year period, +76.9% in local currencies) with a margin of29.1% (prior-year period:23.1% ).
Outlook
- For 2025, Bachem is raising its guidance to between
13% and18% sales growth in local currencies. - Bachem confirms its outlook for an EBITDA margin in 2025 in local currencies in the high twenties.
- The company plans to make investments of more than CHF 400 million in 2025.
- Based on current orders, the company aims for annual sales of more than CHF 1 billion and an EBITDA margin of over
30% in 2026.
A black and white page with numbersAI-generated content may be incorrect.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10552/259916_figure1.jpg
Thomas Meier, CEO of Bachem, on the results for the first half of the year:
"We achieved strong sales growth in the first half of this year and are on a good path to meeting our annual goals. The impact of our ongoing operational excellence measures is becoming more visible. These measures allow us to meet the consistently high demand for peptides even more effectively. Our expansion project Building K is on track to add significant production capacity for our customers. I would particularly like to thank our more than 2 300 colleagues who are making this tremendous development possible.”
Group results
The Bachem Group (SIX: BANB) achieved sales of CHF 313.0 million in the first half of 2025 (+
Operating income before depreciation and amortization (EBITDA) amounted to CHF 91.0 million (+
As a result, the EBITDA margin was
Net income increased to CHF 50.1 million (+
Sales by product category
The Commercial API category achieved sales of CHF 168.4 million (first half of 2024: CHF 127.2 million, +
In the clinical drug development category (CMC Development), sales increased to CHF 123.7 million (first half of 2024: CHF 90.4 million, +
The research chemicals and specialties business (Research & Specialties) delivered CHF 20.8 million (first half of 2024: CHF 22.8 million, -
Substantial capacity expansion
Bachem is pursuing an investment program to expand capacity at all sites. CHF 129.1 million were invested in the first half of 2025 with significant volumes to be invested in the second half of the year. In addition to expansion, Bachem is also continuously optimizing the utilization of existing buildings and facilities through operational improvements.
Bachem began construction of its most advanced production plant for large volumes of peptides and oligonucleotides in 2021 (building “K”) in Bubendorf. The project is on track. First manufacturing lines are commissioned, and technical production activities are progressing. Conditional upon regulatory inspections, Bachem expects GMP production to begin within the course of the second half of 2025. The successful ramp-up of commercial production in the building is a key prerequisite for achieving the revenue target in 2026.
Bachem is planning for a further manufacturing site in Sisslerfeld in the Swiss municipality of Eiken. Bachem has submitted its site development plan (“Entwicklungsrichtplan”) to the authorities and first construction applications are planned for this year.
Bachem continues to invest in its entire network of sites, focusing on site-specific core competencies. In the US, high-volume capacity at the Vista site is being expanded. In Torrance, Bachem is focusing on promising small-volume clinical projects, while investments at the Vionnaz site in Western Switzerland are aimed at securing the supply of key precursors.
Outlook
For 2025 Bachem expects sales growth in local currencies between
The Half-Year Report 2025 and the presentation for the analyst- and media call are available on the website under the following link: https://www.bachem.com/about-bachem/investors-and-media/reports-and-presentations/
Financial Calendar
March 12, 2026 Publication of Annual Report 2025;
Media and Analyst conference
April 29, 2026 Annual General Meeting (financial year 2025)
July 30, 2026 Publication of Half-Year Report 2026
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and sites in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.
| For more information | |
| Media Dr. Daniel Grotzky Head Group Communications Tel.: +41 58 595 2021 | Investors Barbora Blaha Head Investor Relations Tel.: +41 58 595 0573 Email: ir@bachem.com |
This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259916
FAQ
What were Bachem's (BCHMY) H1 2025 financial results?
What is Bachem's revenue guidance for 2025?
How much is Bachem investing in capacity expansion?
What are Bachem's financial targets for 2026?
How did Bachem's different product categories perform in H1 2025?
